

**AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA430)
NICE GUIDANCE ISSUED JANUARY 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation
Advice No: 3116 – November 2016**

Sofosbuvir/velpatasvir (Epclusa[®]▼) 400 mg/100 mg film-coated tablets

Submission by Gilead Sciences

Recommendation of AWMSG

Sofosbuvir/velpatasvir (Epclusa[®]▼) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis C virus infection in adults.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent to or lower than the WPAS price.

Additional note:

- AWMSG recommend that sofosbuvir/velpatasvir (Epclusa[®]▼) is used in accordance with the All Wales hepatitis C roll out programme

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2417), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3116:
Sofosbuvir/velpatasvir (Epclusa[®]) 400 mg/100 mg film-coated tablets. November 2016.